Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OncoGenex Pharmaceuticals Inc.

Division of Achieve Life Sciences Inc.
www.oncogenex.com

Latest From OncoGenex Pharmaceuticals Inc.

Pipeline Watch: Phase III Readouts For Guselkumab, Volanesorsen And Dupilumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Ionis: Another Shot At The Commercial Market And Sustainable Profits

Spinraza, launched by partner Biogen, is the antisense developer’s newest drug to reach the market. Ionis plans to file its first wholly-owned drug, volanesorsen, later this year.

Business Strategies Launches

Deal Watch: Taking Care Of Business Before J.P. Morgan

Under Momenta/CSL autoimmune partnership, Momenta can opt in to co-development or commercialization on recombinant Fc receptor modulator or just earn a revenue stream from CSL’s efforts with the preclinical candidate. Pieris and Servier sign broad-based immuno-oncology collaboration, while Arena hands off the disappointing Belviq to Eisai.

Deals Business Strategies

PIPELINE WATCH: Phase III Trials Start In Atypical HUS, Fabry Disease And Colorectal Cancer

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Sonus Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Achieve Life Sciences Inc.
  • Senior Management
  • Scott Cormack, Pres. & CEO
    John A Bencich, VP, CFO
    Cindy Jacobs, MD, PhD, EVP, CMO
    Jaime Welch, VP, Mktg. & Corp. Communications
  • Contact Info
  • OncoGenex Pharmaceuticals Inc.
    Phone: (425) 686-1500
    1522 217th Pl. SE
    Ste. 100
    Bothell, WA 98021
    USA
UsernamePublicRestriction

Register